Therapeutic Effects and Safety of Mirtazapine for Insomnia in Major Depressive Disorder: Findings from a 6-Week Open-Label Pre- and Post-Intervention Study
Mirtazapine treatment was associated with significant improvements in depression, insomnia, and all QoL parameters, with increased appetite and weight gain being the most common adverse effects. Further randomized controlled comparator studies will be beneficial for healthcare providers to improve the clinical care of MDD patients with insomnia.
Authors
- Kishore Joshi (ORCID: https://orcid.org/0000-0003-1079-5356)
- Mahfuza Tayeba Yasmin
- Nayem Akhter Abbassi (ORCID: https://orcid.org/0000-0002-6640-1507)
- Dipesh Sonawane
- Nadia Afroz (ORCID: https://orcid.org/0009-0005-3000-7507)
- Rubina Hossain
- Suyog Mehta (ORCID: https://orcid.org/0000-0001-7553-4128)
- Ahsan Aziz Sarkar (ORCID: https://orcid.org/0000-0002-8800-8669)
- Syed Reazur Rahman
- Mahbub Hasan (ORCID: https://orcid.org/0000-0003-4301-5272)
- Abdullah Al Mamun (ORCID: https://orcid.org/0000-0002-6746-6097)
- Tahmid Noor Rahman
- Helal Uddin Ahmed (ORCID: https://orcid.org/0000-0003-0463-1822)
- Sameer Rao (ORCID: https://orcid.org/0000-0002-5393-9471)
- Mohammad Tariqul Alam (ORCID: https://orcid.org/0000-0003-1581-7366)
- Muhammad Zillur Rahman Khan (ORCID: https://orcid.org/0000-0001-7006-7444)
- Taiyeb Ibna Zahangir (ORCID: https://orcid.org/0009-0001-8347-3780)
- Afroza Rahman Lopa
- AKM Khaleequzzaman
Institutions
- Sun Pharma Advanced Research (India) (IN)
- National Institute of Cardiovascular Diseases (BD)
- Shaheed Suhrawardy Medical College (BD)
- National Institute of Mental Health (CZ)
- Dhaka Medical College and Hospital (BD)
Publication Details
- Journal
- Neuropsychobiology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1159/000547983
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00